Table 2 Triple-negative breast cancers cases: distribution according to miR-30a (5p and 3p) expression, demographics and clinical pathological features

From: A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness

   miR-30a-5p   miR-30a-3p  
  Total (N=59) Lowa (N=29) Higha (N=30) P-value Lowa (N=29) Higha (N=30) P-value
Median follow-up (months) 63.2 61.0 65.4 0.87c 51.3 67.7 0.06c
Median age at diagnosis (yrs) 51 49 52 0.50c 52 50 0.13c
  No. (%) No. (%) No. (%)   No. (%) No. (%)  
Tumor sizeb
 T1 28 (52.8) 12 (42.9) 16 (64.0) 0.09d 11 (39.3) 17 (68.0) 0.06d
 T2 22 (41.5) 13 (46.4) 9 (36.0)   14 (50.0) 8 (32.0)  
 T3–T4 3 (5.7) 3 (10.7) 0 (0.0)   3 (10.7) 0 (0.0)  
Lymph nodesb
 N0 28 (47.5) 10 (35.7) 18 (75.0) 0.01d 9 (32.1) 19 (79.2) <0.001d
 N+ 24 (40.7) 18 (64.3) 6 (25.0)   19 (67.9) 5 (20.8)  
Metastasis
 M0 54 (91.5) 28 (96.6) 26 (86.7) 0.35d 27 (93.1) 27 (90.0) 1.00d
 M+ 5 (8.5) 1 (3.5) 4 (13.3)   2 (6.9) 4 (10.0)  
TNM stage
 I 19 (32.2) 8 (27.6) 11 (36.7) 0.80d 7 (24.1) 12 (40.0) 0.43d
 II 25 (42.4) 13 (44.8) 12 (40.0)   13 (44.8) 12 (40.0)  
 III–IV 15 (25.4) 8 (27.6) 7 (23.3)   9 (31.0) 6 (20.0)  
Tumor gradeb
 G1–G2 3 (5.1) 1 (3.6) 2 (6.7) 1.00d 0 (0.0) 3 (10.4) 0.24d
 G3 55 (93.2) 27 (96.4) 28 (93.3)   29 (100.0) 26 (89.7)  
Radiation treatmentb
 No 23 (45.1) 10 (38.5) 13 (52.0) 0.40d 11 (45.8) 12 (55.6) 1.00d
 Yes 28 (54.9) 16 (61.5) 12 (48.0)   13 (54.2) 15 (44.4)  
Pharmacological treatmentb
 No 9 (16.1) 3 (11.1) 6 (20.7) 0.47d 4 (14.8) 5 (17.2) 1.00d
 Yes 47 (83.9) 24 (88.9) 23 (79.3)   23 (85.2) 24 (82.8)  
Drugsb
 Anthracycline 21 (47.7) 14 (60.9) 7 (33.3) 0.23d 11 (52.4) 10 (43.5) 0.73d
 Anthracycline/Taxanes 11 (25.0) 4 (17.4) 7 (33.3)   4 (19.0) 7 (30.4)  
 CMF 12 (27.3) 5 (21.7) 7 (33.3)   6 (28.6) 6 (26.1)  
  1. CMF cyclophosphamide, methotrexate and 5-fluorouracil
  2. aThe median value was used as cut-off
  3. bThe sum does not add up to the total because of some missing values
  4. cMann–Whitney–Wilcoxon test
  5. dFisher’s exact test